9-ING-41 (Elraglusib) is a maleimide-based ATP-competitive and selective glycogen synthase kinase-3beta (GSK-3beta) inhibitor with an IC50 of 0.71 µM. 9-ING-41 significantly leads to cell cycle arrest, autophagy and apoptosis in cancer cells. 9-ING-41 has anticancer activity and has the potential for enhancing the antitumor effects of chemotherapeutic agents[1][2][3][4].
Molecular Weight:
404.35
Purity:
99.13
CAS Number:
[1034895-42-5]
Formula:
C22H13FN2O5
Target:
Apoptosis,Autophagy,GSK-3
Application Notes:
MCE Product type: Reference compound
* VAT and and shipping costs not included. Errors and price changes excepted
